Related Experiment Video
Updated: Feb 23, 2026
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
A novel treatment approach for retinoblastoma by targeting epithelial growth factor receptor expression with a shRNA
Yong Chai1, Juhua Xiao2, Yunyan Du3
1Department of Ophthalmology, Jiangxi Children's Hospital, Nanchang, Jiangxi Province, 330006 China.
Objectives:
Non-invasive treatment options for retinoblastoma (RB), the most common malignant eye tumor among children, are lacking. Epithelial growth factor receptor (EGFR) accelerates cell proliferation, survival, and invasion of many tumors including RB. However, RB treatment by targeting EGFR has not yet been researched. In the current study, we investigated the effect of EGFR down-regulation on RB progression using shRNA lentiviral vectors.
Materials And Methods:
EGFR expression in Weri-Rb-1 cells was down-regulated by EGFR shRNA-bearing lentiviral vectors. Cell death, proliferation, cell cycle as well as invasion after EGFR down-regulation were determined. Further signaling pathway analysis was done by Western blot.
Results:
Our results revealed that EGFR shRNA could specifically down-regulate EGFR expression and down-regulation of this protein promoted cell death. Further analysis on cell cycle demonstrated that EGFR down-regulation also suppressed cell proliferation by arresting cells at G1 phase. Invasion analysis showed that EGFR down-regulation suppressed cell invasion and was correlated with alteration in the expression of matrix metalloproteinases 2 and 9. Further signaling pathway analysis revealed that EGFR down-regulation mediated RB progression was through PI3K/AKT/mTOR signaling pathway.
Conclusion:
Our study revealed that EGFR down-regulation, through the PI3K/AKT/mTOR signaling pathway, could inhibit RB progression by promoting cell death while suppressing cell proliferation and invasion. The findings of our study indicated that down-regulation of EGFR using shRNA lentiviral vectors may offer a novel non-invasive treatment for RB.
Insights
Targeting epithelial growth factor receptor (EGFR) with shRNA lentiviral vectors inhibits retinoblastoma progression. This novel approach promotes cell death and suppresses proliferation and invasion, offering a potential non-invasive treatment for this childhood eye cancer.
Area of Science:
- Oncology
- Ophthalmology
- Molecular Biology
Background:
- Retinoblastoma (RB) is a common childhood eye cancer with limited non-invasive treatment options.
- Epithelial growth factor receptor (EGFR) is implicated in the progression of various tumors, including RB, by promoting cell proliferation, survival, and invasion.
- Targeting EGFR for RB treatment remains an unexplored therapeutic avenue.
Purpose of the Study:
- To investigate the efficacy of down-regulating EGFR in inhibiting retinoblastoma progression.
- To explore the underlying molecular mechanisms by which EGFR down-regulation affects RB cells.
- To assess the potential of EGFR-targeted shRNA lentiviral vectors as a novel non-invasive treatment for RB.
Main Methods:
- EGFR expression was reduced in Weri-Rb-1 cells using EGFR shRNA-bearing lentiviral vectors.
- Cell death, proliferation, cell cycle, and invasion assays were performed to evaluate the effects of EGFR down-regulation.
- Western blotting was utilized for signaling pathway analysis.
Main Results:
- EGFR shRNA effectively down-regulated EGFR expression, leading to increased cell death.
- EGFR down-regulation suppressed cell proliferation by inducing G1 phase arrest.
- Inhibition of cell invasion was observed, correlated with altered expression of matrix metalloproteinases 2 and 9.
- EGFR down-regulation impacted RB progression via the PI3K/AKT/mTOR signaling pathway.
Conclusions:
- EGFR down-regulation effectively inhibits retinoblastoma progression by promoting cell death and suppressing proliferation and invasion.
- The PI3K/AKT/mTOR signaling pathway is a key mediator of EGFR's role in RB progression.
- EGFR-targeted shRNA lentiviral vectors represent a promising strategy for a novel non-invasive treatment for retinoblastoma.
